A false advertising class-action lawsuit against Quincy Bioscience was dismissed
in June 2016. The complaint
, which was originally filed in state court in March 2015 and transferred to federal court in September 2015, alleged that the company advertises the products as “Clinically Tested” to “Improve Memory” by 7.5% within 8 days, 10% within 30 days, and 20% within 90 days and support “Healthy Brain Function” when, in reality, the product does not support memory or brain function at all and the company makes the claims without adequate scientific evidence to support them. The reasons for the dismissal have not been disclosed. The named plaintiff’s individual claims were dismissed with prejudice
while the class members’ claims were dismissed without prejudice
. (Musgrave et al v. Quincy Bioscience, LLC et al
, Case No. 15-cv-4505, N. D. CA.)
For more information about TINA.org’s coverage of Prevagen, click here.